Open-label studies showed that treatment with lumacaftor-ivacaftor was generally safe and well-tolerated in children aged 6–11 years with CF homozygous for the F508del-CFTR mutation and also in children aged 2–5 years old [100,101]. This evidence concerns the gene CFTR and cystic fibrosis.